Within the context of a medical cardiology practice, especially navigating among patients with inadequate responses to ezetimibe and/or statin intolerance or resistance, how do you sequence PCSK9 inhibitors in your LDL-C lowering treatment plans?

Within the context of a medical cardiology practice, especially navigating among patients with inadequate responses to ezetimibe and/or statin intolerance or resistance, how do you sequence PCSK9 inhibitors in your LDL-C lowering treatment plans?

CLICK HERE FOR CME CREDIT

Within the context of a medical cardiology practice, especially navigating among patients with inadequate responses to ezetimibe and/or statin intolerance or resistance, how do you sequence PCSK9 inhibitors in your LDL-C lowering treatment plans?

 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY